Features | Partner Sites | Information | LinkXpress
Sign In
PURITAN MEDICAL
Demo Company
GLOBETECH PUBLISHING LLC

Bead-Based Capture Kit Eases Enrichment and Cleanup of DNA Libraries

By BiotechDaily International staff writers
Posted on 13 Jun 2013
Image: The new SeqCap EZ Pure Capture Bead Kit (Photo courtesy of Roche Nimblegen).
Image: The new SeqCap EZ Pure Capture Bead Kit (Photo courtesy of Roche Nimblegen).
A newly released bead-based capture system was designed to provide genomic researchers with a sensitive and robust method for capture and purification of DNA sample libraries enabling high-quality targeted sequencing results.

NimbleGen (Madison, WI, USA), the genomics products subsidiary of Roche (Basel, Switzerland), recently announced the global launch of its SeqCap EZ Pure Capture Bead Kit.

This kit offers researchers a set of capture and purification beads used to prevent secondary capture and isolate DNA sample libraries from contaminants during amplification. It, therefore, represents a sensitive and robust method for cleanup of DNA sample libraries for high-quality DNA sequencing results


The kit includes SeqCap EZ Capture Beads and SeqCap EZ Purification Beads. Capture beads are used to recover the captured DNA sample from the hybridization of the DNA sample library and the SeqCap EZ Library. Purification beads are used to purify the amplified DNA sample library and the amplified capture DNA sample library after LM-PCR (ligase mediated - polymerase chain reaction). Roche provides a comprehensive set of reagents and probe pools for superior target enrichment performance. The probe pools include exome libraries, gene panels, and custom designs.

In addition to the SeqCap EZ Capture Beads Kit, Roche NimbleGen has released new disease-specific target enrichment panels for clinical research applications. These include the SeqCap EZ Comprehensive Cancer Design, which covers 578 genes implicated in a wide range of common and rare cancers, and the SeqCap EZ Neurology Panel Design, which covers 256 genes associated with 87 neurological disorders, including Parkinson’s disease, Alzheimer’s disease, epilepsy, and autism.


Related Links:

NimbleGen
Roche


Channels

Drug Discovery

view channel
Image: Cancer cells were treated with a control (left) and the overstimulating compound MCB-613 (right) (Photo courtesy of Dr. Lei Wang, Baylor University College of Medicine).

Drug Candidate Propels Cancer Cells into Fatal Overdrive

A candidate drug that destroys cancer cells by stimulating them to produce more proteins than the cells can actually process was shown to kill a wide variety of cancer cells in culture and to inhibit tumor... Read more

Business

view channel

Innovative Microbial Diagnostics Developer Acquired by Biomedical Giant

A biotech company noted for its development of innovative products in the field of molecular microbiology diagnostics has been acquired by one of the world's largest biomedical corporations. GeneWEAVE BioSciences, Inc.(Los Gatos, CA, USA) and Roche (Basel, Switzerland) have announced that Roche will be purchasing the... Read more
 
Copyright © 2000-2015 Globetech Media. All rights reserved.